
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau





English

(10) International Publication Number WO 2023/239422 A3

(51) International Patent Classification:

 A61K 31/5025 (2006.01)
 A61P 1/00 (2006.01)

 A61K 31/4192 (2006.01)
 A61P 35/00 (2006.01)

 A61K 47/55 (2017.01)

(21) International Application Number:

PCT/US2022/078542

(22) International Filing Date:

21 October 2022 (21.10.2022)

(25) Filing Language:

(26) Publication Language: English

(30) Priority Data:


63/270,762 22 October 2021 (22.10.2021) US 63/315,777 02 March 2022 (02.03.2022) US

(71) Applicants: UNIVERSITY OF HOUSTON SYSTEM [US/US]; 4800 Calhoun Road, Houston, TX 77204 (US). TRACT PHARMACEUTICALS, INC. [US/US]; 29

South Main Street, Suite 305, West Hartford, CT 06107 (US).

- (72) Inventors: XIAN, Wa; 5 Saint Christopher Ct., Sugar Land, TX 77479 (US). MCKEON, Frank; 5 Saint Christopher Ct., Sugar Land, TX 77479 (US). WANG, Shan; 6220 Alder Dr. #3906, Houston, TX 77096 (US). LIEW, Audrey-ann; 8877 Frankway Dr. #4456, Houston, TX 77096 (US). VINCENT, Matthew; 12 Quimby Lane, Amesbury, MA 01913 (US).
- (74) Agent: HIGHLANDER, Steven, L.; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

(54) Title: METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES



FIGS. 1A-F

(57) **Abstract:** The present disclosure provides methods and formulations for treating a patient suffering from one or more of chronic inflammatory injury, metaplasia, dysplasia or cancer of esophageal tissue and gastric tissue, which method comprises administering to the patient an agent that selectively kills or inhibits the proliferation or differentiation of pathogenic Barrett's Esophagus stem cells (BESCs) or Gastric Intestinal Metaplasia stem cells (GIMSCs) relative to normal regenerative esophageal stem cells or gastric stem cells in the tissue in which the BESCs or GIMSCs are found.

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- (88) Date of publication of the international search report: 04 April 2024 (04.04.2024)

International application No PCT/US2022/078542

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/5025 A61K31/4192 A61K47/55 A61P1/00 A61P35/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2021/175326 A1 (BEIJING SINOTAU BIO PHARMACEUTICALS TECH CO LTD [CN]) 10 September 2021 (2021-09-10) the whole document	1-41,45
Y	SUN HAIYING ET AL: "Design, Synthesis, and Characterization of a Potent, Nonpeptide, Cell-Permeable, Bivalent Smac Mimetic That Concurrently Targets Both the BIR2 and BIR3 Domains in XIAP", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, no. 49, 14 November 2007 (2007-11-14), pages 15279-15294, XP093112919, ISSN: 0002-7863, DOI: 10.1021/ja074725f the whole document	1-41,45

Further documents are listed in the continuation of Box C.	See patent family annex.
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"X" document of particular relevance;; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance;; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
12 January 2024	12/03/2024
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Moutafidou, Nikoleta

International application No. PCT/US2022/078542

INTERNATIONAL SEARCH REPORT

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)				
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:				
Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:				
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).				
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)				
This International Searching Authority found multiple inventions in this international application, as follows:				
see additional sheet				
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.				
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.				
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:				
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims;; it is covered by claims Nos.: 1-41, 45				
The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.				
No protest accompanied the payment of additional search fees.				

International application No
PCT/US2022/078542

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2020/219963 A1 (UNIV HOUSTON SYSTEM [US]; UNIV TEXAS [US] ET AL.) 29 October 2020 (2020-10-29) page 119; claims; figure 1	1-41,45
x	RU 2 696 310 C1 (ASTEKS TERAPYUTIKS LTD [GB]) 1 August 2019 (2019-08-01)	1-8,16, 17,22, 23, 26-29, 31,32,45
Y	the whole document	1-41,45
x	WO 2013/043591 A1 (EINSTEIN COLL MED [US]; LIBUTTI STEVEN K [US]; YUAN ZIQIANG [US]) 28 March 2013 (2013-03-28)	1-3,5-7, 16,17, 22,23, 26-29, 31,32
Y	the whole document	1-41,45
х	DIZDAR LEVENT ET AL: "Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer", ONCOLOGY LETTERS, 9 January 2018 (2018-01-09), XP093113155, GR ISSN: 1792-1074, DOI: 10.3892/o1.2018.7755	1-3,5-7, 16,17, 22,23, 26-29, 31,32
Y	the whole document	1-41,45
A	DE FALCO VALENTINA ET AL: "Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 98, no. 5, 1 May 2013 (2013-05-01), pages E811-E819, XP093113394, US ISSN: 0021-972X, DOI: 10.1210/jc.2012-2672 the whole document	1-41,45

Information on patent family members

International application No
PCT/US2022/078542

EP 4115902 A1 11-0	
WO 2021175326 A1 10-09-2021 CN 115243719 A 25-1 EP 4115902 A1 11-0	
EP 4115902 A1 11-0	10-2022
	01-2023
JP 2023518132 A 27-0	04-2023
	04-2023
	9-2021
WO 2020219963 A1 29-10-2020 AU 2020263577 A1 18-1	L1-2021
CA 3135020 A1 29-1	LO-2020
CN 114007671 A 01-0	2-2022
EP 3962559 A1 09-0	3-2022
IL 287573 A 01-1	L2-2021
JP 2022529535 A 22-0	06-2022
KR 20220007867 A 19-0	01-2022
US 2022202792 A1 30-0	06-2022
WO 2020219963 A1 29-1	LO-2020
TV 0000310	
	06-2016
	02-2019
	08-2017
)9-2023)6-2015
	08-2015 08-2016
)2-2019
	L1-2022
)7-2022
)8-2021 10-2016
	07-2016 07-2020
	17-2020 12-2021
	L2-2021 L2-2021
)2-2022)2-2019
)8-2019)8-2020
)8-2020)8-2022
	01-2017
)5-2019 L1-2020
	08-2016
	08-2016 09-2021
)7-2021)7-2021
	10-2021 10-2022
	LO-2022 LO-2019
)5-2022
)7-2022)7-2016
	L2-2021
	08-2021
)9-2021)9-2021
	01-2018
	LO-2018
DG 10201000102W A 30-1	07-2016
SG 11201604795R A 28-0	L2-2021
	3-2021
SI 3083616 T1 31-1	
SI 3083616 T1 31-1 TW 201609724 A 16-0	12-2017
SI 3083616 T1 31-1 TW 201609724 A 16-0 US 2017029419 A1 02-0)2-2017)3-2018
SI 3083616 T1 31-1 TW 201609724 A 16-0 US 2017029419 A1 02-0 US 2018065959 A1 08-0	3-2018
SI 3083616 T1 31-1 TW 201609724 A 16-0 US 2017029419 A1 02-0 US 2018065959 A1 08-0 US 2020325134 A1 15-1	03-2018 10-2020
SI 3083616 T1 31-1 TW 201609724 A 16-0 US 2017029419 A1 02-0 US 2018065959 A1 08-0 US 2020325134 A1 15-1 US 2022204503 A1 30-0	03-2018 10-2020 06-2022
SI 3083616 T1 31-1 TW 201609724 A 16-0 US 2017029419 A1 02-0 US 2018065959 A1 08-0 US 2020325134 A1 15-1 US 2022204503 A1 30-0 US 2023227450 A1 20-0	03-2018 10-2020

Information on patent family members

International application No
PCT/US2022/078542

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2013043591	A1	28-03-2013	NONE	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-41, 45

Use of IAP inhibitors and devices comprising them, for treating conditions of esophageal tissue.

2. claim: 42

A bioadhesive nanoparticle per se.

3. claim: 43

A submucosal retentive formulation per se.

4. claim: 44

An injectable thermogel per se.

5. claim: 46

A formulation comprising an IAP inhibitor agent and an ESO Regenerative agent per se.